Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days

Trial Profile

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2013

At a glance

  • Drugs Insulin detemir (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Biomarker; Therapeutic Use
  • Acronyms SNIFF-LONG 21
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jul 2013 Secondary endpoint (working memory) results presented at the 2013 Alzheimer's Association International Conference .
    • 14 Jul 2013 Primary endpoint 'Verbal-rating-scale' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top